The three pillars in treating antibody-mediated encephalitis

Area of Science:

• Neurology
• Immunology

Background:

• Antibody-mediated encephalitis (AE) requires prompt treatment for optimal outcomes.
• Current treatment strategies for AE, including antiseizure and antipsychotic medications, are debated.
• Standardized treatment protocols are lacking, particularly for severe or refractory AE cases.

Purpose of the Study:

• To review and contrast the primary treatment modalities for antibody-mediated encephalitis.
• To highlight the significance of antiseizure therapy, antipsychotic therapy, and immunotherapy/tumor resection in managing AE.
• To underscore the need for updated guidelines and standardized procedures in AE management.

Main Methods:

• Literature review of current treatment options for antibody-mediated encephalitis.
• Comparative analysis of antiseizure, antipsychotic, and immunotherapy/tumor resection strategies.
• Discussion of evidence and expert opinion on AE management.

Main Results:

• Early immunotherapy initiation significantly impacts AE disease course.
• The roles of antiseizure and antipsychotic therapies in AE are controversial but warrant standardized approaches.
• Immunotherapy and tumor resection remain critical interventions for AE.

Conclusions:

• Standardized treatment protocols are essential for antibody-mediated encephalitis, particularly for severe presentations.
• Further research and guidelines are needed for managing refractory AE.
• A multi-modal approach combining immunotherapy, antiseizure, and antipsychotic therapies is key to improving AE patient outcomes.